|
Vaccine Detail
E. coli FimH with CFA and then IFA |
Vaccine Information |
- Type: Subunit vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: E. coli FimH (Langermann et al., 1997)
- FimH from E. coli str. K-12 substr. MG1655
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Baboon Response
- Vaccination Protocol: C3H mice were immunized with the various FimH vaccines and challenged with the NU14 clinical isolate 9 weeks after the primary immunization.
- Challenge Protocol: Intraurethral inoculation of C3H mice with 5 × 10^7 type 1–piliated E. coli (strain NU14) resulted in a highly reproducible colonization of the mouse bladder (Langermann et al., 1997). Piliated bacteria persisted in the bladder for at least 7 days [10^4 colony-forming units (CFU)/bladder] and produced ascending infection into the kidney.
- Efficacy: Vaccinated animals exhibited a 100- to 1000-fold reduction in the number of organisms recovered from the bladders as compared with adjuvant- or FimC-immunized controls (Langermann et al., 1997).
|
References |
Langermann et al., 1997: Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (New York, N.Y.). 1997; 276(5312); 607-611. [PubMed: 9110982].
|
|